Mode of antiviral action of silver nanoparticles against HIV-1
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Silver nanoparticles have proven to exert antiviral activity against HIV-1 at non-cytotoxic concentrations, but the mechanism underlying their HIV-inhibitory activity has not been not fully elucidated. In this study, silver nanoparticles are evaluated to elucidate their mode of antiviral action against HIV-1 using a panel of different in vitro assays. RESULTS: Our data suggest that silver nanoparticles exert anti-HIV activity at an early stage of viral replication, most likely as a virucidal agent or as an inhibitor of viral entry. Silver nanoparticles bind to gp120 in a manner that prevents CD4-dependent virion binding, fusion, and infectivity, acting as an effective virucidal agent against cell-free virus (laboratory strains, clinical isolates, T and M tropic strains, and resistant strains) and cell-associated virus. Besides, silver nanoparticles inhibit post-entry stages of the HIV-1 life cycle. CONCLUSIONS: These properties make them a broad-spectrum agent not prone to inducing resistance that could be used preventively against a wide variety of circulating HIV-1 strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The bactericidal effect of silver nanoparticles
Morones, J. R., Elechiguerra, J. L., Camacho, A., Holt, K., Kouri, J. B., Ramírez, J. T., & Yacaman, M. J. (2005) · Nanotechnology · doi:10.1088/0957-4484/16/10/059 · Cited by 6,668
Sondi, I., & Salopek-Sondi, B. (2004) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2004.02.012 · Cited by 5,986
Antimicrobial effects of silver nanoparticles
Kim, J. S., Kuk, E., Yu, K. N., Kim, J.-H., Park, S. J., Lee, H. J., Kim, S. H., Park, Y. K., Park, Y. H., Hwang, C.-Y., et al. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.12.001 · Cited by 4,918
Antiseptics and Disinfectants: Activity, Action, and Resistance
McDonnell, G., & Russell, A. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.147 · Cited by 4,780
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
Interaction of silver nanoparticles with HIV-1
Elechiguerra, J. L., Burt, J. L., Morones, J. R., Camacho-Bragado, A., Gao, X., Lara, H. H., & Yacaman, M. J. (2005) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-3-6 · Cited by 1,709
Self-citationThe HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Proteomic Analysis of the Mode of Antibacterial Action of Silver Nanoparticles
Lok, C.-N., Ho, C.-M., Chen, R., He, Q.-Y., Yu, W.-Y., Sun, H., Tam, P. K.-H., Chiu, J.-F., & Che, C.-M. (2006) · Journal of Proteome Research · doi:10.1021/pr0504079 · Cited by 1,581
Shahverdi, A. R., Fakhimi, A., Shahverdi, H. R., & Minaian, S. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2007.02.001 · Cited by 1,299
Silver-nanoparticle-embedded antimicrobial paints based on vegetable oil
Kumar, A., Vemula, P. K., Ajayan, P. M., & John, G. (2008) · Nature Materials · doi:10.1038/nmat2099 · Cited by 1,033
Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., & Gregory, T. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86956-3 · Cited by 985
Biological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria
Lara, H. H., Ayala-Núñez, N. V., Ixtepan Turrent, L. D. C., & Rodríguez Padilla, C. (2010) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-009-0211-3 · Cited by 804
Self-citationCellular responses induced by silver nanoparticles: In vitro studies
Arora, S., Jain, J., Rajwade, J. M., & Paknikar, K. M. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.04.009 · Cited by 736
Silver Nanoparticles Inhibit Hepatitis B virus Replication
Lu, L., Sun, R. W.-Y., Chen, R., Hui, C.-K., Ho, C.-M., Luk, J. M., Lau, G. K., & Che, C.-M. (2008) · Antiviral Therapy · doi:10.1177/135965350801300210 · Cited by 603
Antimicrobial effect of surgical masks coated with nanoparticles
Li, Y., Leung, P., Yao, L., Song, Q. W., & Newton, E. (2006) · Journal of Hospital Infection · doi:10.1016/j.jhin.2005.04.015 · Cited by 572 · cited 1×
“Silver’s mode of action is presumed to be dependent on Ag ions, which strongly inhibit bacterial growth through suppression of respiratory enzymes and electron transport components and through interference with DNA functions [10].”
BackgroundA Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox Virus Plaque Formation
Rogers, J. V., Parkinson, C. V., Choi, Y. W., Speshock, J. L., & Hussain, S. M. (2008) · Nanoscale Research Letters · doi:10.1007/s11671-008-9128-2 · Cited by 453
Sun, R. W.-Y., Chen, R., Chung, N. P.-Y., Ho, C.-M., Lin, C.-L. S., & Che, C.-M. (2005) · Chemical Communications · doi:10.1039/b510984a · Cited by 440
Baram-Pinto, D., Shukla, S., Perkas, N., Gedanken, A., & Sarid, R. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900215b · Cited by 368
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832214100 · Cited by 357
The role of Acticoat™ with nanocrystalline silver in the management of burns
Dunn, K., & Edwards-Jones, V. (2004) · Burns · doi:10.1016/s0305-4179(04)90000-9 · Cited by 349
Lawn, S. D., Butera, S. T., & Folks, T. M. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.753-777.2001 · Cited by 313
Formation of silver nanoparticles by laser ablation of a silver target in NaCl solution
Bae, C. H., Nam, S. H., & Park, S. M. (2002) · Applied Surface Science · doi:10.1016/s0169-4332(02)00430-0 · Cited by 272 · cited 1×
“Although silver nanoparticles feature characteristic absorption at 400-500 nm [28] no interference to the absorption signals of the ELISA assay was observed.”
BackgroundSilver Nanoparticles Inhibit Replication of Respiratory Syncytial Virus
Sun, L., Singh, A. K., Vig, K., Pillai, S. R., & Singh, S. R. (2008) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2008.012 · Cited by 189
Antisepsis, disinfection, and sterilization types, action, and resistance
McDonnell, G. E. (2007) · Cited by 186
Witvrouw, M., Fikkert, V., Pluymers, W., Matthews, B., Mardel, K., Schols, D., Raff, J., Debyser, Z., De Clercq, E., Holan, G., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12484-4 · Cited by 168
Bhol, K. C., & Schechter, P. J. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06575.x · Cited by 157
NEURATH, A. R., Strick, N., Li, Y., & Debnath, A. K. (2001) · BMC Infectious Diseases · doi:10.1186/1471-2334-1-17 · Cited by 98
A Bioassay for HIV-1 Based on Env-CD4 Interaction
Ciminale, V., Felber, B. K., Campbell, M., & Pavlakis, G. N. (1990) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1990.6.1281 · Cited by 86
Silver resistance in Escherichia coli R1
Starodub, M. E., & Trevors, J. T. (1989) · Journal of Medical Microbiology · doi:10.1099/00222615-29-2-101 · Cited by 59
Yang, Q., Stephen, A. G., Adelsberger, J. W., Roberts, P. E., Zhu, W., Currens, M. J., Feng, Y.-X., Crise, B. J., Gorelick, R. J., Rein, A. R., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.10.6122-6133.2005 · Cited by 54
Chavda, S., Griffin, P. C., Han-Liu, Z., Keys, B., Vekony, M. A., & Cann, A. J. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-11-3249 · Cited by 37
Multi-targeting the Entrance Door to Block HIV-1
Borkow, G., & Lapidot, A. (2005) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005053174645 · Cited by 37
Cited by
Zhang, X.-F., Liu, Z.-G., Shen, W., & Gurunathan, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091534 · Cited by 3,220
Ahmed, S., Ahmad, M., Swami, B. L., & Ikram, S. (2016) · Journal of Advanced Research · doi:10.1016/j.jare.2015.02.007 · Cited by 3,028
Kango, S., Kalia, S., Celli, A., Njuguna, J., Habibi, Y., & Kumar, R. (2013) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2013.02.003 · Cited by 2,157
Metal-Based Nanoparticles as Antimicrobial Agents: An Overview
Sánchez-López, E., Gomes, D., Esteruelas, G., Bonilla, L., Lopez-Machado, A. L., Galindo, R., Cano, A., Espina, M., Ettcheto, M., Camins, A., et al. (2020) · Nanomaterials · doi:10.3390/nano10020292 · Cited by 1,474
“This problem was overcome by the conversion of CuNPs to CuONPs, the latter having greater stability but with slightly less activity [99].”
BackgroundNanosilver as a new generation of nanoproduct in biomedical applications
Chaloupka, K., Malam, Y., & Seifalian, A. M. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.07.006 · Cited by 1,451
Metadata
- Authors
- Lara, H. H., Ayala-Nuñez, N. V., Ixtepan-Turrent, L., & Rodriguez-Padilla, C.
- Venue
- Journal of Nanobiotechnology
- Published
- 2010
- Volume
- 8
- Issue
- 1
- Pages
- 1
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W2145617208
- Cited by
- 1,061
- References
- 33
- FWCI
- 21.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.